The 2nd European Myeloma Network (EMN) was held virtually, on March 3–6, 2021.

Experts in the field came together online to discuss and debate the latest updates in the field.

View all videos

EMN 2021

European Myeloma Network (EMN)
03–06 March 2021 | Virtual Meeting

First results of the 2nd H2H of iBTKs: the ALPINE study. With a 15 months follow up.
So different population from ELEVATE RR #iwCLL2021 @PeterHillmen #CLL

4

⭐@ninashah33 of @UofCalifornia gives us all the latest developments on the use of alloCAR-T therapies ⭐

Watch: 👉http://ow.ly/k1V050G7DAQ👈

@SocietyofHemOnc #SOHO2021 #HemOnc #ImmunoOnc #CART #BloodCancerAwarenessMonth #CancelBloodCancer #BCAM

In advance of our 2nd debate at #iwCLL2021 between Peter Dreger and @drjgauthier, which type of cellular therapy do you prefer for your patients with CLL?

Very nice description of a very difficult clinical situation: Richter’s Transformation with CNS involvement. Presented by @YucaiWangMD @WeiDing3 at #iwCLL2021

Load More...

EMN 2021

European Myeloma Network (EMN)
03–06 March 2021 | Virtual Meeting

The 2nd European Myeloma Network (EMN) was held virtually, on March 3–6, 2021.

Experts in the field came together online to discuss and debate the latest updates in the field.

View all videos

First results of the 2nd H2H of iBTKs: the ALPINE study. With a 15 months follow up.
So different population from ELEVATE RR #iwCLL2021 @PeterHillmen #CLL

4

⭐@ninashah33 of @UofCalifornia gives us all the latest developments on the use of alloCAR-T therapies ⭐

Watch: 👉http://ow.ly/k1V050G7DAQ👈

@SocietyofHemOnc #SOHO2021 #HemOnc #ImmunoOnc #CART #BloodCancerAwarenessMonth #CancelBloodCancer #BCAM

In advance of our 2nd debate at #iwCLL2021 between Peter Dreger and @drjgauthier, which type of cellular therapy do you prefer for your patients with CLL?

Very nice description of a very difficult clinical situation: Richter’s Transformation with CNS involvement. Presented by @YucaiWangMD @WeiDing3 at #iwCLL2021

Load More...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter